Genea Pty Ltd

Genea Pty Ltd is a large, multi-site fertility and reproductive medicine laboratory headquartered in Sydney, Australia, with clinical and laboratory operations across major Australian cities (Sydney, Melbourne, Brisbane, Canberra, Newcastle, Perth, and Wollongong) and affiliated centers in Thailand and India. The company operates both clinical IVF services and specialized diagnostic pathology laboratories that serve fertility patients, medical practitioners, and assisted reproduction clinics throughout the Asia-Pacific region.

The laboratory's core service offering encompasses comprehensive andrology and reproductive genetics testing. Andrology services include semen analysis (measuring sperm count, motility, vitality, and morphology), sperm viability assessment, cryopreservation for fertility preservation, post-vasectomy examinations, cervical mucus analysis, and sperm antibody testing. These services support male factor fertility diagnosis and assisted conception treatment planning.

Genea's genetic testing division specializes in preimplantation genetic testing (PGT), a critical service for in-vitro fertilization patients seeking to screen embryos before transfer. The laboratory offers PGT-A (preimplantation genetic testing for aneuploidy, detecting chromosomal abnormalities), PGT-M (for monogenic disorders, screening for over 350 hereditary conditions including cystic fibrosis, thalassemia, Huntington disease, and sickle cell anemia), and PGT-SR (structural rearrangement testing for parental translocations and inversions). This genetic testing scope places Genea among the most comprehensive reproductive genetics laboratories in the Southern Hemisphere.

The laboratory also operates an advanced embryology division providing specialized cell culture and monitoring services. These include time-lapse embryo monitoring using proprietary incubation technology (Geri® incubator), embryo culture with branded culture media formulations (Gems® media), assisted hatching procedures, and cryopreservation services for embryos and gametes. Genea manufactures some of its own laboratory equipment and culture media through its Genea Biomedx subsidiary, ensuring tight quality control and integration across the diagnostic and therapeutic pipeline.

Quality assurance and regulatory compliance are foundational to operations. The company maintains NATA accreditation (National Association of Testing Authorities, Australia) under ISO 15189:2022 standards across multiple laboratory locations, including facilities in Bella Vista (accredited since 1998), Sydney South, Newcastle, Melbourne, Canberra, and Brisbane. Additionally, Genea Biomedx's manufacturing operations hold ISO 13485 certification for medical device quality management. These accreditations confirm competency in human pathology testing, clinical laboratory management, and diagnostic accuracy standards required for fertility treatment support.

The organization employs approximately 424 staff across its network and is backed by LVP (formerly Liverpool Partners), a private equity investor. Genea competes in the global assisted reproduction diagnostics market, with partnerships extending to international genomics providers and research institutions. The company positions itself as a key infrastructure provider supporting the fertility treatment industry throughout Australasia, combining clinical service delivery with diagnostic laboratory science and specialized embryology expertise. For testing laboratories on LabQuotes serving analytical, materials, or pharmaceutical sectors, Genea represents a specialized model of clinical pathology laboratory operations and genetic testing methodology relevant to understanding the higher end of diagnostic laboratory capabilities.